Shanghai Junshi Biosciences Co., Ltd (HKEX: 1877; SSE: 688180) announced that its phase 3 clinical study NEOTORCH met primary endpoints ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE